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Abstract
Background: Although in recent years, the introduction of novel chemotherapy protocols has improved the
outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a
foremost concern. In this context, a major contribution was provided by the introduction of the nucleoside analog
nelarabine, approved for salvage treatment of T-ALL patients with refractory/relapsed disease. However, nelarabine
could induce a life-threatening, dose-dependent neurotoxicity. To improve nelarabine efficacy, we have analyzed its
molecular targets, testing selective inhibitors of such targets in combination with nelarabine.
Methods: The effectiveness of nelarabine as single agent or in combination with PI3K, Bcl2, and MEK inhibitors was
evaluated on human T-ALL cell lines and primary T-ALL refractory/relapsed lymphoblasts. The efficacy of signal
modulators in terms of cytotoxicity, induction of apoptosis, and changes in gene and protein expression was
assessed by flow cytometry, western blotting, and quantitative real-time PCR in T-ALL settings.
Results: Treatment with nelarabine as a single agent identified two groups of T-ALL cell lines, one sensitive and
one resistant to the drug. Whereas sensitive T-ALL cells showed a significant increase of apoptosis and a strong
down-modulation of PI3K signaling, resistant T-ALL cells showed a hyperactivation of AKT and MEK/ERK1/2
signaling pathways, not caused by differences in the expression of nelarabine transporters or metabolic activators.
We then studied the combination of nelarabine with the PI3K inhibitors (both pan and dual γ/δ inhibitors), with the
Bcl2 specific inhibitor ABT199, and with the MEK inhibitor trametinib on both T-ALL cell lines and patient samples
at relapse, which displayed constitutive activation of PI3K signaling and resistance to nelarabine alone. The
combination with the pan PI3K inhibitor ZSTK-474 was the most effective in inhibiting the growth of T-ALL cells
and was synergistic in decreasing cell survival and inducing apoptosis in nelarabine-resistant T-ALL cells. The drug
combination caused AKT dephosphorylation and a downregulation of Bcl2, while nelarabine alone induced an
increase in p-AKT and Bcl2 signaling in the resistant T-ALL cells and relapsed patient samples.
Conclusions: These findings indicate that nelarabine in combination with PI3K inhibitors may be a promising
therapeutic strategy for the treatment of T-ALL relapsed patients.
Keywords: PI3K signaling, Apoptosis, Drug resistance, Combination therapy
* Correspondence: alberto.martelli@unibo.it; francesca.chiarini@cnr.it
†Equal contributors
1Department of Biomedical and Neuromotor Sciences, University of Bologna,
Bologna, Italy
5Institute of Molecular Genetics, Rizzoli Orthopedic Institute, National
Research Council, Bologna, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lonetti et al. Journal of Hematology & Oncology  (2016) 9:114 
DOI 10.1186/s13045-016-0344-4
Background
T cell acute lymphoblastic leukemia (T-ALL) is a
hematologic malignancy resulting from the transform-
ation of T cell progenitors that accounts for 15 % of
pediatric and 25 % of adult ALL cases. Despite improve-
ments in cure rates, the outcome of T-ALL patients with
chemoresistant or relapsed leukemia is still poor [1].
T-ALL requires aggressive chemotherapy. To minimize
and overcome the detrimental effects of therapeutic regi-
mens, it is essential to identify novel molecular targets
in T-ALL and test selective inhibitors of such targets [2].
Thus, major efforts are being made to develop targeted
molecules against deregulated signaling pathways sus-
taining T-ALL cell growth/survival/drug resistance.
Indeed, selective inhibitors of deregulated pathways
could be used together with chemotherapy, allowing for
a lower dosage of chemotherapeutic drugs which should
minimize toxic side effects. The nucleoside analog nelar-
abine is a prodrug of the deoxyguanosine analog 9-β-D-
arabinofuranosylguanine (Ara-G) [3, 4]. Nelarabine is
rapidly metabolized in the plasma by an adenosine
deaminase into the active metabolite Ara-G, the latter
having a much longer plasma half-life and reaching
higher plasma concentrations [5]. Ara-G is taken up by
leukemia cells via the nitrobenzylthioinosine-sensitive
nucleoside membrane transporter equilibrative nucleo-
side transporter 1 (ENT1) [6]. Ara-G is then phosphory-
lated to Ara-G monophosphate by the deoxycytidine and
deoxyguanosine kinase (dCK and dGK, respectively). It
is then phosphorylated to its triphosphate form Ara-
GTP, which in turn competes with dGTP for DNA poly-
merase and is subsequently incorporated into DNA,
resulting in termination of DNA synthesis [7]. Since
2005, nelarabine has been approved for the treatment of
both pediatric and adult T-ALL patients who have
refractory or progressive disease after previous chemo-
therapy regimens [5, 8]. Nelarabine is preferentially
cytotoxic to T lymphoblasts through the accumulation
of Ara-GTP, which occurs to a greater extent in T cells
than in B cells, resulting in inhibition of ribonucleotide
reductase and subsequent DNA synthesis [9, 10]. Nelara-
bine as monotherapy was effective in inducing
complete/partial responses in both children and adults
with refractory or relapsed T-ALL [3, 8, 11]. Given the
impressive single-agent activity seen in refractory or
relapsed T-ALL, substantial interest developed in evalu-
ating nelarabine in the up-front treatment of T-ALL.
Clinical trials have shown that nelarabine could be safely
combined with intensive chemotherapy (BFM-86) in the
frontline therapy of pediatric T-ALL, and in combination
with hyper-CVAD in the frontline therapy for adults
with T-ALL [12–14]. Of 40 patients with T-ALL or T
lymphoblastic lymphoma (T-LL), the CR rate was 89 %
in T-ALL and 94 % in T-LL. Overall survival at 3 years
was 63 % [14]. However, in recent years, it is emerging
that nelarabine could induce a significant neurotoxicity,
particularly when given in conjunction with multi-agent
chemotherapy regimens [15, 16]. Patients who suffered
from nelarabine neurotoxicity displayed myelopathy and
severe necrotic changes in the nervous system [17], as
well as irreversible paresthesia or paraplegia [17, 18]. Im-
portantly, nelarabine-induced neurotoxicity depends on
the dosage [19]. Therefore, a combined therapy with
signal transduction modulators could allow for the use
of a lower dosage of nelarabine, resulting in a lower inci-
dence and/or seriousness of neurotoxicity and resistance.
However, there is no information regarding how aber-
rantly activated signaling pathways could influence
T-ALL cell sensitivity to nelarabine. In contrast, in
recent years, valuable information has been collected
regarding aberrantly activated signaling pathways influ-
encing leukemia cell sensitivity to fludarabine [20], a
nucleoside analog which is employed in the treatment of
B cell chronic lymphocytic leukemia (CLL), or to clofar-
abine, a nucleoside analog used for treating acute
myeloid leukemia (AML) patients [21, 22]. The effects of
phosphoinositide 3-kinase (PI3K) inhibition on fludara-
bine sensitivity could be related to changes in the
expression of Bcl2 family proteins (Mcl-1 and Bim) [23,
24] which are also involved in clofarabine sensitivity in
AML cells [22]. Importantly, PI3K/AKT/mammalian
target of rapamycin (mTOR) signaling inhibition
enhanced fludarabine-induced cell death in a T-ALL cell
line (CEM-S) [25]. Moreover, a combination of clofara-
bine and temsirolimus, an mTOR inhibitor, displayed
synergistic cytotoxic effects in AML cell lines and
primary samples, and showed an encouraging clinical
activity [21, 26]. A recent study underscored a potential
role for Bcl2 family proteins in determining nelarabine
resistance, in an Ara-G-resistant T-ALL cell line variant,
established by serial incubation with Ara-G (the active
metabolite of nelarabine) [27]. In this study, anti-
apoptotic Bcl-xL was augmented and pro-apoptotic Bax
and Bad were reduced in CEM/Ara-G cells, suggesting
refractoriness to Ara-G-induced apoptosis [27].
Here, we demonstrate that in nelarabine-resistant T-
ALL cell lines, there is a hyperactivation of PI3K/AKT/
mTOR, ERK1/2 and Bcl2 signaling in response to nelar-
abine. Treatment with ZSTK-474 (a pan PI3K p110
inhibitor [28]), IPI-145 (Duvelisib@, a γ/δ PI3K p110
inhibitor [29]), GSK1120212 (Trametinib@, a MEK in-
hibitor [30]), or ABT199 (Venetoclax@, a Bcl2 inhibitor
[31]) synergized with nelarabine in reducing cell survival
in nelarabine-resistant T-ALL cells. ZSTK-474 was the
most potent drug in inducing cell death in combination
with nelarabine, allowing for a lower dosage of nelara-
bine even in samples from T-ALL relapsed patients.
Moreover, nelarabine combined with ZSTK-474 induced
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a dephosphorylation of AKT and ERK1/2 and induced
an increase in the expression of Bax and Bak pro-
apoptotic members of Bcl2 family in T-ALL cells resist-
ant to nelarabine. The combination of nelarabine with
ZSTK-474 was able to induce a marked cell death in
MOLT-4 cells co-cultured with HS-5 human HS-5
stromal cells, which mimic bone marrow (BM) micro-
environment. These observations suggest the possibility
to combine nelarabine together with selective inhibitors
of the PI3K signaling pathway, to improve the efficacy of
T-ALL treatment of relapsed/refractory patients.
Results
Treatment with nelarabine identifies two groups of T-ALL
cell lines: one sensitive and one resistant
The effects of nelarabine on a panel of T-ALL cell lines
were tested by incubating the cells for 48 h with increas-
ing concentrations of the drug and then analyzing the
rate of cell viability, using MTT assays. Two significantly
different groups of cell lines were outlined: a sensitive
and a resistant group of cell lines. Cell viability
decreased in a concentration-dependent fashion, and the
IC50 values ranged between 2 and 5.5 μM for sensitive
cell lines (Fig. 1a, b). However, it was observed that
some cell lines were markedly resistant to nelarabine
treatment. In particular, LOUCY, ALL-SIL, MOLT-16,
and PEER cells did not reach an IC50 at the concentra-
tions used, after 48 h of treatment (Fig. 1a, b). The most
resistant cell line was LOUCY, with an IC50 of 300 μM,
calculated with the CalcuSyn software. This cell line is
representative of ETP-ALL, a T-ALL subtype with a very
poor prognosis [29]. In vitro studies, using T-ALL cells,
demonstrated that reduction of cell viability of induced
by either nelarabine or Ara-G was comparable (Fig. 1c).
Importantly, nelarabine induced a significant reduction
in viable cell number, in sensitive versus resistant cell
lines, as documented by absolute count (Fig. 1d).
Nelarabine treatment promotes apoptosis in sensitive T-
ALL cell lines
To evaluate whether the effects of nelarabine on cell
viability could be related to apoptosis, flow cytometric
analysis was performed on the sensitive cell lines. In
response to treatment with 5 μM nelarabine (2 μM for
MOLT-4 cells), we detected a marked increase in the
percentage of early apoptotic (positive for Annexin V)
and/or late apoptotic (positive for both Annexin V and
PI) cells after 48 h of treatment of T-ALL cell lines
MOLT-4, JURKAT, P12-ICHIKAWA, and DND41
(Fig. 2a). Apoptosis was further investigated by western
blotting, which documented a time-dependent cleavage
of caspase 8, caspase 9, caspase 3, and poly(ADP-ri-
bose) polymerase (PARP) in response to nelarabine
treatment (Fig. 2b). All cell lines analyzed display
phosphorylated AKT, which is indicative of constitutive
activation of PI3K signaling pathway [32]. We
Fig. 1 Nelarabine induces cytotoxic effects in T-ALL cell lines. a Cell viability was assessed by MTT analysis of T-ALL cell lines treated for 48 h with
increasing concentrations of nelarabine. Results are the mean of at least three different experiments ± SD. b Identification of nelarabine sensitive
and resistant cell lines based on IC50 values. c MTT analysis of T-ALL cell lines treated with nelarabine or Ara-G, at the same increasing concentrations
for 48 h. Results are the mean of at least three different experiments ± SD. d Flow cytometric analysis of absolute cell count with eBeads123 and PI
exclusion of T-ALL cells treated with nelarabine for 48 h. All 13 cell lines shown in Fig. 1a (five sensitive and eight resistant) were analyzed. Data were
plotted and grouped. Results are the mean of three different experiments ± SD. Asterisks indicate statistically significant differences with respect to
untreated cells (***P < 0.001)
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examined the effects of nelarabine on the most import-
ant signaling downstream targets of PI3K/AKT/mTOR
and MEK pathways. In all T-ALL sensitive cell lines,
nelarabine treatment induced a marked decrease of
phosphorylated AKT at Ser473, S6 ribosomal protein
(S6RP) at Ser235/236, and GSK3β at Ser9 after 48 h of
treatment, suggesting that PI3K/AKT/mTOR pathway
is down-modulated by nelarabine (Fig. 2c). Moreover,
in all sensitive cell lines analyzed, ERK phosphorylation
was impaired by the treatment, indicating also a down-
regulation of the MEK pathway. In all cell lines
evaluated, total protein levels were unaffected. It was
demonstrated that DNA fragmentation is associated
with nucleoside analog-induced apoptosis [27, 33]. To
better understand the mechanism of nelarabine-
induced apoptosis, we have analyzed the phosphoryl-
ation of H2AX. Indeed, the rapid phosphorylation of
H2AX on Ser139 (γH2AX) is an early cellular response
to double-strand breaks (DSBs). This phosphorylation
event is one of the most well-established chromatin
modifications linked to DNA damage. Moreover, the
production of reactive oxygen species (ROS) coincides
with the appearance of DNA damage and partially
contributes to the DNA damage accumulated, followed
by apoptosis at later time points [34]. MOLT-4 and
Jurkat cell lines were treated with nelarabine for 7 and
Fig. 2 Nelarabine induces apoptosis in a group of sensitive T-ALL cell lines and modulates PI3K/AKT/mTOR and MEK signaling. a Flow cytometric
analysis of Annexin V-FITC/PI stained T-ALL cells treated with nelarabine (5 μM for JURKAT, P12-ICHIKAWA, and DND-41 cells, 2 μM MOLT-4 cells)
48 h. The percentages of early apoptotic cells (Annexin-V FITC+/PI−; bottom right quadrant) and late apoptotic/necrotic cells (Annexin-V FITC+/PI+;
top right quadrant) are plotted. The histograms are representative of three separate experiments. CTRL untreated cells. b Western blot analysis
documenting cleavage of caspase-8, caspase-9, caspase-3, and PARP by nelarabine. Cells were treated with nelarabine (5 μM for JURKAT,
P12-ICHIKAWA, and DND-41 cells, 2 μM MOLT-4 cells) for the indicated times, collected, and then lysed. Fifty micrograms of each lysate were
electrophoresed on SDS-PAGE gels followed by transfer onto a nitrocellulose membrane. c Nelarabine induces a decrease in the phosphorylation
status of critical components of the PI3K/AKT/mTOR signaling pathway, as well as p-ERK (Thr202) levels in T-ALL sensitive cell lines. Western blot
analysis documenting the reduction of p-AKT (Ser473), p-S6RP, p-GSK3β (Ser9), and p-ERK (Thr202). Antibody to β-actin served as a loading con-
trol. Molecular weights are indicated on the right
Lonetti et al. Journal of Hematology & Oncology  (2016) 9:114 Page 4 of 16
24 h, and γH2AX was evaluated by flow cytometry in
both control and treated cells. We observed a time-
dependent increase of γH2AX in response to nelarabine
in both cell lines compared to controls (untreated
cells). In addition, we measured the intracellular ROS
levels in response to nelarabine treatment, and we
observed an increase of ROS production following 1
and 24 h of nelarabine treatment. The induction of
DNA damage by nelarabine is consistent with a
reduction in cell viability and an increase in caspases/
PARP activity. These findings suggest that nelarabine-
induced apoptosis could depend on these mechanisms
(Additional file 1: Figure S1).
Resistance to nelarabine is not dependent on differential
expression of ENT1/2 transporters and is partly due to
upregulation of PI3K/AKT/mTOR, MEK, and Bcl2 signaling
To find potential explanations for differences in nelara-
bine sensitivity displayed by T-ALL cell lines, we
determined mRNA expression levels of ENT1 and ENT2
nelarabine transporters, which could have a role in
nelarabine cellular uptake [35]. Both ENT1 and ENT2
were expressed in all T-ALL cell lines, but there were no
differences between the sensitive versus resistant group
in the levels of expression of these transporters (Fig. 3a).
Moreover, nelarabine treatment did not affect ENT1/2
mRNA levels in T-ALL sensitive or resistant groups
Fig. 3 Nelarabine resistance does not depend on expression of ENT1/2 transporters and is partly due to upregulation of PI3K, MEK, and Bcl2
signaling. a Gene qRT-PCR analysis for ENT1 and ENT2 mRNA expression in T-ALL cell lines, untreated or treated with nelarabine for 48 h. Results
are the mean from three different experiments ± SD. b qRT-PCR analysis for Bcl2 and Bcl-xL mRNA expression in T-ALL cell lines, untreated or
treated with nelarabine for 48 h. Results are the mean from three different experiments ± SD. c Western blotting documenting an increase of
p-AKT (Ser473), as well as p-ERK (Thr202), and Bcl2 in T-ALL resistant cell lines treated with nelarabine. Antibody to β-actin served as a loading
control. d Densitometric analysis of western blotting shown in c was performed to quantify Bcl2 protein in resistant cell lines treated with
nelarabine at different time points. The amount of protein was normalized to β-actin density and expressed as fold change compared to control
(ratio = Bcl2 treated/Bcl2 control). Densitometry scanning of the bands was performed using a Chemidoc 810 Imager with the appropriate
software (UVP, Upland, CA, USA). Statistical analyses were performed with the Dunnett’s multiple comparison test. Results showed a significant
increase in the Bcl2 protein expression only in PEER cell line, at 48-h treatment, P < 0.05. e Flow cytometric functional efflux activity assay for
170 kDa P-glycoprotein (P-gp) in CEM-R (overexpressing P-gp) cells. The assay is based on extrusion of the fluorescent P-gp substrate, Rhodamine
123. The efflux activity of P-gp is highly temperature sensitive; P-gp functions optimally at 37 °C, but is inactive at 4 °C. When preloaded with
Rhodamine 123 and incubated at 4 °C (CTRL), CEM-R cells retained the dye and consequently exhibited high fluorescence. Conversely, cells
incubated at 37 °C (CTRL) effluxed the dye. CEM-R cells treated with nelarabine at 37 °C displayed a marked decrease in the pump activity. f Flow
cytometric analysis of surface P-gp expression of CEM-R cells treated with nelarabine for 48 h (10 μM). The histograms are representative of two
separate experiments
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(Fig. 3a). By western blotting, we have also evaluated the
expression of the two enzymes, dCK and dGK, involved
in the purine metabolism. However, no significant differ-
ences in the expression of these enzymes in sensitive
versus resistant group were detected (Additional file 2:
Figure S2).
A recent study underscored a potential role for Bcl2
family members in determining nelarabine resistance, as
a nelarabine-resistant T-ALL cell line displayed
increased anti-apoptotic Bcl-xL levels, whereas pro-
apoptotic Bax and Bad levels were decreased [27]. To
better understand the role of Bcl2 family, it was first
investigated the gene expression of Bcl2 and Bcl-xL
genes in sensitive and resistant to nelarabine cell lines.
Analyses of gene expression demonstrated no significant
differences in the levels of mRNA, between sensitive and
resistant to nelarabine T-ALL cell lines under basal
conditions (Fig. 3b, upper panel). Moreover, treatment
with nelarabine did not induce significant differences in
the gene expression of resistant or sensitive cell lines
(Fig. 3b, lower panel). By western blotting, we analyzed
the effects of nelarabine on the expression of anti-
apoptotic Bcl2 and Bcl-xL proteins in resistant cell lines.
Among T-ALL cell lines, LOUCY cell line showed the
highest level of expression of Bcl2 under basal condi-
tions (Additional file 3: Figure S3). Nelarabine treatment
affected the expression of Bcl2 in all resistant cell lines
analyzed. However, a significant increase of Bcl2 protein
expression was observed only in PEER cells, after 48-h
treatment (Fig. 3c, d).
Aberrant activation of several signal transduction
pathways enhances survival, proliferation, and drug
resistance of leukemic cells. PI3K/AKT/mTOR pathway
is frequently overactive in T-ALL cells, and is very
important for drug resistance. Therefore, it was investi-
gated the status of this pathway in nelarabine resistance.
T-ALL cell lines showing high IC50 to nelarabine treat-
ment were treated for 6, 16, 24, 48 h with the drug
(10 μM) and then analyzed by western blotting for the
activation of PI3K/AKT/mTOR or MEK/ERK pathways.
In ALL-SIL, LOUCY, MOLT-16, and PEER cell lines,
treatment with nelarabine induced a time-dependent
increase in p-AKT (Ser473), indicating an overactivation
of PI3K/AKT signaling (Fig. 3c). It was also investigated
the status of the MEK/ERK1/2 pathway in these resistant
cell lines. This signaling cascade is also involved in
leukemic cell survival and drug resistance [36]. Western
blotting analysis documented that nelarabine dramatic-
ally increased p-ERK (Thr202) levels in all resistant cell
lines analyzed, especially in MOLT-16 and PEER cells
(Fig. 3b). The results presented above indicated these
signaling cascades as attractive targets for the
development of new therapeutic strategies for T-ALL
cells resistant to nelarabine treatment.
Effects of nelarabine on 170-kDa P-glycoprotein
No information is at present available regarding the
effects of 170-kDa P-glycoprotein (P-gp), one of the
major determinants of multidrug resistance in acute
leukemias [37], on nelarabine sensitivity.
In contrast, it is known that pharmacological inhib-
ition of P-gp activity increased fludarabine sensitivity in
CLL cells [38]. Furthermore, P-gp expression is known
to be under the control of PI3K/AKT/mTOR signaling
in acute leukemia cells [39, 40]. We noticed that CEM-R
cells, which overexpress P-gp [41], were less sensitive to
nelarabine than parental CEM-S cells. Therefore, we set
out to investigate the relevance of P-gp in nelarabine
sensitivity. A functional assay for P-gp activity, based on
Rhodamine 123 extrusion, demonstrated that nelarabine
treatment (48 h) was able to decrease P-gp activity in
CEM-R cells (Fig. 3d). Moreover, flow cytometric
analysis documented that nelarabine negatively affected
P-gp surface expression in these cells (Fig. 3e). There-
fore, our findings indicated that nelarabine actually
decreased P-gp activity and expression in CEM-R cells.
Thus, it is unlikely that the different sensitivity to
nelarabine displayed by CEM-S and CEM-R cells could
be dependent on P-gp expression.
Nelarabine combined with ZSTK-474 affects PI3K/AKT sig-
naling and modulates p-ERK and Bcl2 family members in
T-ALL cells resistant to nelarabine
To better understand the role of PI3K, MEK/ERK1/2,
and Bcl2 signaling, it was investigated the effect of the
combination of nelarabine with the pan PI3K inhibitor
ZSTK-474, the γ/δ PI3K p110 inhibitor IPI-145, the
MEK inhibitor trametinib, or the Bcl2 inhibitor ABT199.
The effects of the different drug combinations on
nelarabine-resistant T-ALL cell lines were analyzed by
treating the cells with increasing concentrations of the
drugs and then measuring the rates of survival by MTT
assays at 48 h. Cell lines (LOUCY, MOLT-16, PEER, and
ALL-SIL) were cultured in the presence of nelarabine or
the abovementioned drugs, either alone or in
combination at a fixed ratio (Fig. 4a). The combined
treatment with ZSTK-474 was highly effective in
inducing cytotoxicity in all the resistant cell lines
analyzed, indicating that PI3K is at least in part involved
in nelarabine resistance. ZSTK-474 was synergistic with
nelarabine also in P-gp overexpressing CEM-R cells
(Additional file 4: Figure S4).
A prominent role for PI3K p110γ and δ isoforms has
been proposed in T-ALL [42]. Therefore, the effects of
the p110 γ/δ dual inhibitor IPI-145 alone or in combin-
ation with nelarabine were also assessed. However, the
pan PI3K inhibitor ZSTK-474 was more efficacious than
IPI-145 although IPI-145 combined with nelarabine was
also synergistic. The combination index (CI) values,
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Fig. 4 (See legend on next page.)
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calculated with CalcuSyn software for dose-effect
analysis, indicated the existence of a strong synergism
for both drugs (CI <0.5) (Fig. 4a).
Treatment with the MEK inhibitor trametinib was also
synergistic, but less potent in inhibiting cell viability in
all cell lines studied. Interestingly, MOLT-16 and PEER
cells, which displayed the most marked activation of
MEK/ERK1/2 signaling after nelarabine treatment, were
the most sensitive to trametinib. The Bcl2 inhibitor,
ABT199, was very efficacious in inducing cell growth
impairment, especially in ALL-SIL and LOUCY cell lines
(Fig. 4a). LOUCY cells are representative of ETP-ALL
and displayed the highest Bcl2 expression and sensitive-
ness to Bcl2 inhibition by ABT199 [43].
To better assess the role of PI3K signaling, western
blot analyses with an antibody to p-AKT (Ser473) were
carried out, demonstrating a marked decrease in
response to the combination of nelarabine with ZSTK-
474 treatment after 48 h, in all cell lines analyzed
(Fig. 4b). Also, one of the downstream substrates of
mTORC1 (S6RP) was efficiently dephosphorylated by
the drug combination in all cell lines. Furthermore, the
combination of nelarabine with ZSTK-474 was able to
induce a decrease in the Bcl2 and Bcl-xL protein
expression in all cell lines resistant to nelarabine alone,
except for LOUCY cells, which were not affected by the
combined treatment (Fig. 4c). The combination was also
capable of inducing an increase in the expression of
pro-apoptotic Bax and Bak proteins after 48 h of
treatment (Fig. 4c).
To assess whether nelarabine directly affected PI3K/
AKT and MEK/ERK1/2 signaling pathways, we have
treated T-ALL resistant to nelarabine cells with selective
inhibitors of these two axes. In particular, we employed
LY294002 (PI3K inhibitor), CCI-779 (mTOR allosteric
inhibitor), and trametinib (MEK1/2 inhibitor). As shown
in Additional file 5: Figure S5, we confirmed that treat-
ment with nelarabine as a single agent upregulated p-
AKT (Ser473) and p-ERK (Thr202), whereas LY294002,
CCI-779 and trametinib as single agents did not.
LY294002 was not able to dephosphorylate AKT and to
synergize with nelarabine, in contrast to the PI3K inhibi-
tor ZSTK-474. This result could be dependent on the
LY294002 concentration we used, 10 μM to avoid
aspecific effects on signaling pathways, whereas pub-
lished data employed LY294002 at higher concentrations
[41]. Combining nelarabine with CCI-779 inhibitor re-
sulted in upregulated PI3K and MEK signaling as dem-
onstrated by an increase in p-AKT (Ser473) and p-
ERK (Thr202), compared to untreated or CCI-779
treated cells, and indicating a major role of nelarabine in
hyperactivating these axes. To ascertain CCI-779 effects,
we evaluated one of its downstream key targets S6RP,
which was strongly dephosphorylated by the treatment.
Trametinib was able to completely dephosphorylate ERK
both alone and in combination with nelarabine, but it
did not perturbate significantly AKT phosphorylation.
However, also in this case, the combination of trametinib
with nelarabine increased p-AKT (Ser473) compared to
T-ALL cells untreated or treated with nelarabine/trame-
tinib as single agents. These results suggest that the up-
regulation of PI3K/AKT and MEK/ERK1/2 signaling
pathways are directly affected by nelarabine treatment.
Moreover, ZSTK-474 strongly counteracted nelarabine
effects on both PI3K and MEK/ERK1/2 signaling path-
ways compared to the other specific inhibitors
employed.
The combination of nelarabine with ZSTK-474 restored
sensitiveness in MOLT-4 and P12-ICHIKAWA cells co-
cultured with of HS-5 stromal cells and down-modulated
PI3K and Bcl2 signaling in a system which mimics BM
microenvironment
We employed the human stromal cell line HS-5, known
to provide long-term support for hematopoietic progeni-
tors [44]. It was investigated whether cell death induced by
nelarabine treatment in sensitive cell lines could be im-
paired by co-culturing T-ALL cells with HS-5, which mimic
the BM microenvironment. MOLT-4 and P12-ICHIKAWA
cells displayed a significant protection from apoptosis, in-
duced by the co-culture with HS-5 stromal cells at 48 h of
treatment, as demonstrated by staining with Annexin V/PI
and flow cytometric analysis of apoptosis (Fig. 5a, b). The
combination of nelarabine and ZSTK-474 was efficient in
decreasing resistance to nelarabine, induced in these two
cell lines by the co-culture with HS-5 stromal cells. More-
over, to better assess the effectiveness of a combined treat-
ment, we examined MOLT-4 cells for the levels of p-AKT
(See figure on previous page.)
Fig. 4 Nelarabine combined with the PI3K inhibitor ZSTK-474 induces cytotoxicity and causes a down-modulation of PI3K, MEK, and Bcl2
signaling. a Cell viability assays of T-ALL cell lines treated for 48 h with increasing concentrations of nelarabine combined with the pan PI3K p110
inhibitor ZSTK-474, the γ/δ PI3K p110 inhibitor IPI-145, the MEK inhibitor trametinib, or the Bcl2 inhibitor ABT199 at fixed ratios. Results are the
mean of three different experiments ± SD. b Western blotting analyses documenting a marked decrease in the phosphorylation of AKT, S6RP, and
ERK in T-ALL cell lines treated with the combination of nelarabine (10 μM) and ZSTK-474 (2.5 μM). Molecular weights are indicated on the right.
One representative of three different experiments is shown. c Western blotting analyses of T-ALL cell lines treated with the combination of
nelarabine (10 μM) and ZSTK-474 (2.5 μM) for 48 h. The combined treatment decreased the levels of expression of Bcl2 and Bcl-xL and increased
the expression of the pro-apoptotic Bax and Bak proteins. Antibody to β-actin served as a loading control. Molecular weights are indicated on the
right. One representative of three different experiments is shown
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(Ser473) and Bcl2, with or without the support of HS-5
stromal cells, using flow cytometry. Flow cytometric ana-
lysis documented a decrease in the levels of p-
AKT (Ser473) in nelarabine-treated samples without the
support of stromal cells (Fig. 5c). Interestingly, nelarabine
induced a hyperphosphorylation of AKT in MOLT-4
cells supported by the co-culture with HS-5 cells,
while the treatment with ZSTK-474 was able to in-
duce a marked reduction of p-AKT and Bcl2 expres-
sion. Overall, these findings demonstrated that the
combination of nelarabine with ZSTK-474 has a po-
tent cytotoxic activity also in co-culture conditions
which mimic the BM microenvironment.
HS-5 stromal cells protect MOLT-4 cells from nelarabine
cytotoxicity at least in part through CXCL12/CXCR4
interactions
It is well established that interactions between the
chemokine CXCL12, secreted by BM stromal cells, and
its receptor CXCR4, expressed on the surface of
Fig. 5 ZSTK-474 restored nelarabine sensitivity in MOLT-4 and P12-ICHIKAWA cells co-cultured with of HS-5 stromal cells and down-modulated
PI3K and Bcl2 signaling. a Flow cytometric analysis of Annexin V-FITC/PI staining in T-ALL cells growing alone or in co-culture system with HS-5
cells and treated with nelarabine (5 μM for P12-ICHIKAWA cells, 2 μM for MOLT-4 cells) in a Transwell@ system. Three hundred seventy-five
thousand T-ALL cells were seeded in the upper chamber of the Transwell@ system. The histograms are representative of three separate
experiments. CTRL untreated cells. b Graph bars indicating apoptotic cells in response to combined treatment in single culture versus co-culture
with HS-5 cells. Asterisks indicate statistically significant differences with respect to untreated cells (***P < 0.001, *P < 0.05). c Flow cytometric
analysis of Annexin V-FITC/PI of MOLT-4 cells growing in co-culture with HS-5 stromal cells and treated with nelarabine 2 μM for 48 h in a
Transwell@ system. The histograms are representative of three separate experiments. d Flow cytometric analysis of p-AKT (Ser473) and Bcl2 in
MOLT-4 cells growing alone or in co-culture with HS-5 stromal cells. The histograms are representative of three separate experiments
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leukemic cells, are very important for protecting
leukemia cells from chemotherapeutic drugs [37, 45].
HS-5 cells secrete CXCL12 [46], while MOLT-4 cells
express high levels of CXCR4 [47]. Therefore, we wanted
to establish whether CXCL12/CXCR interactions were
involved in the protective effects exerted by HS-5 cells
on nelarabine-treated MOLT-4 cells. As shown in
Additional file 6: Figure S6A, AMD3100 (plerixafor),
which selectively blocks the interactions between
CXCL12 and CXCR4 [47], significantly increased the
cytotoxicity of nelarabine in MOLT-4 cells co-cultured
with HS-5 cells in a Transwell@ system.
To document that the CXCR4/CXCL12 axis was
indeed functional in our system, we performed western
blot analysis. The presence of HS-5 cells increased
p-ERK and p-CXCR4 levels in MOLT-4 cells, as
expected [48]. It is worth noting that Ser339 is an amino
acidic residue previously identified as a site for ligand-
induced phosphorylation of CXCR4 [49] and is involved
in ERK1/2 activation [50, 51]. The presence of nelara-
bine did not further increase the phosphorylation or
either ERK or CXCR4. However, AMD3100 dampened
the phosphorylation levels of both ERK and CXCR4
(Additional file 6: Figure S6B).
T-ALL blasts are sensitive to the combination of
nelarabine with ZSTK-474
To better assess the effectiveness of the combination of
nelarabine with ZSTK-474 as a potential therapeutic
strategy in T-ALL, we examined relapsed pediatric
T-ALL patient samples isolated from the bone marrow
or peripheral blood, for the sensitiveness to nelarabine
alone, in vitro. These patients were previously analyzed
for the activation of PI3K signaling, showing high levels
of p-AKT (Ser 473). The effects of nelarabine on patient
lymphoblasts were tested by incubating the cells for 72 h
with increasing concentrations of the drug and then
analyzing the rate of cell viability using MTT assays.
Some patient samples showed high IC50 (>10 μM), while
others were more sensitive to nelarabine alone (IC50
<5 μM) (Fig. 6a). The resistant samples were treated
with nelarabine in combination with ZSTK-474, and ab-
solute cell count/PI staining was assessed by flow cytom-
etry for 24, 48, and 72 h for Pt-3, showing the significant
effects of the combination (Fig. 6b). The combination of
nelarabine with ZSTK-474 was highly effective in
inducing apoptosis in the resistant patient samples
analyzed, showing a marked increase in Annexin V/PI
stained (Fig. 6c, Pt-3). Pt-5 and Pt-6 were also evaluated
by MTT assays with nelarabine in combination with
ZSTK-474 at fixed ratios (nelarabine/ZSTK-474, 4:1).
The synergistic effect was assessed and the combination
indexes (CIs) were calculated with the CalcuSyn
software (Fig. 6d).
Finally, we evaluated the effects of single treatment
with nelarabine or combination with ZSTK-474 on
T-ALL patient samples on the expression levels of
p-AKT (Ser473) and Bcl2. Flow cytometric analysis
documented an increase in the levels of p-AKT in
nelarabine-treated samples, while the treatment with the
combination of nelarabine and ZSTK-474 was able to
induce a marked reduction of p-AKT (Ser473) and Bcl2
expression (Fig. 6e, f ). Overall, these findings demon-
strated that the combination of nelarabine with ZSTK-
474 has a potent cytotoxic activity also in primary cells
from relapsed T-ALL patients with upregulated PI3K/
AKT signaling and resistant to nelarabine in vitro.
Discussion
Despite the continuous efforts in understanding the
molecular complexity of T-ALL, treatments are still
based on chemotherapeutic regimens, and prognosis of
this disease remains poor, especially in the adult and in
chemoresistant/relapsed patients. Nelarabine is a nucleo-
side analog successfully used for the treatment of refrac-
tory/relapsed T-malignancies, including T-ALL and
T-LL [52–54]. Nelarabine as monotherapy is effective in
inducing complete/partial responses in T-ALL patients
[5]. However, it could induce a severe dose-dependent
neurotoxicity. Very little is known of proteins/genes that
could influence nelarabine sensitivity in T-ALL [35, 55].
Here, we evaluated the in vitro efficacy of the adminis-
tration of nelarabine as a single agent in cell lines and
primary blast cells from relapsed T-ALL, to explore
some druggable signaling pathways that influence sensi-
tivity to nelarabine. Indeed, a combined therapy with
signal transduction modulators could allow for the use
of a lower dosage of nelarabine, resulting in a lower
incidence and/or seriousness of neurotoxicity and major
effects of the therapy. Importantly, our in vitro studies,
using T-ALL cell lines, demonstrated that IC50 values of
nelarabine and Ara-G are comparable. The concentra-
tions utilized in these experiments are lower than
plasma levels achievable in Ara-G-treated patients [56].
We have shown that nelarabine reduced cell viability in
a concentration-dependent manner in a group of T-ALL
cell lines and primary patient samples, with an IC50
lower than 5 μM, while other cell lines and relapsed
patients showed resistance to in vitro nelarabine
treatment, with IC50 much higher than 10 μM. The
nelarabine cytotoxic effects in sensitive cell lines
correlated with a significant induction of apoptosis and
cleavage of caspases 8, 9, and 3, and PARP, suggesting
the activation of the extrinsic and intrinsic apoptotic
pathway. Moreover, PI3K signaling and MEK/ERK1/2
pathway resulted down-modulated in all the sensitive
cell lines treated with nelarabine alone. It has been
reported that the levels of expression of ENT1/2
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nucleoside transporters were related to in vitro nelara-
bine sensitivity of T-ALL cell lines and primary samples
[35]. These transporters have been shown to be import-
ant for the Ara-C import, and elevated ENT1 levels have
been reported to explain the high Ara-C sensitivity of
infant ALL [57]. However, a previous work on the
T-ALL cell line CEM-S demonstrated that, while the
cellular transport of forodesine was dependent on
Fig. 6 Nelarabine combined with ZSTK-474 is able to induce a marked cytotoxic effect in relapsed T-ALL patients with upregulated PI3K signaling.
a MTT assays of lymphoblasts from relapsed T-ALL patients (Pts) with activated PI3K signaling treated with nelarabine for 72 h. Data shown are
the mean of at least two different experiments ± SD. b Flow cytometric cell count with eBeads123/PI staining of T-ALL blasts treated with nelarabine
alone or combined with ZSTK-474 for 24, 48,72 h. c Flow cytometric analysis of Annexin V-FITC/PI of T-ALL blasts treated with nelarabine alone or
combined with ZSTK-474. The percentages of early apoptotic cells (Annexin-V FITC+/PI−; bottom right quadrant) and late apoptotic/necrotic cells
(Annexin-V FITC+/PI+; top right quadrant) are plotted. The histograms are representative of two separate experiments. d Cell viability assays of
lymphoblasts from relapsed T-ALL patients treated for 72 h with increasing concentrations of nelarabine alone or combined with the pan PI3K inhibitor
ZSTK-474 at fixed ratios. Results are the mean of two different experiments ± SD. e, f Flow cytometric analysis documenting a decrease of p-
AKT (Ser473) (e) and Bcl2 (f) levels, respectively, in response to the combination of nelarabine and ZSTK-474 at the indicated concentrations for 48 h.
The histograms are representative of two separate experiments
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ENT1/2, forodesine toxicity was not [58]. Recent studies
also showed that ENT1/2 expression levels were not re-
lated to forodesine toxicity levels in T-ALL cells [35].
We have analyzed the expression of ENT1/2 trans-
porters in the sensitive and resistant to nelarabine
groups. In all the T-ALL cells analyzed, we did not find
significant differences between resistant and sensitive
cells as far as the expression of ENT1/2 transporters was
concerned. Furthermore, the levels of expression of
ENT1/2 genes were not modulated by the treatment
with nelarabine in a significant manner. In addition,
Ara-G must be phosphorylated by dCK and dGK to
become an intracellular metabolite and to be incorpo-
rated into DNA [7]. The protein levels of dCK and dGK
were not significantly different in resistant or sensitive
groups, indicating that the resistance to nelarabine in
T-ALL cells could be due to other mechanisms.
Accumulating evidence indicates that the PI3K signaling
is linked to resistance to therapy in several disorders [59,
60]. In hematological malignancies, it has been shown to
support tumor proliferation, viability, and drug resist-
ance. In a recent paper by Silveira et al. [61], it was
shown that PI3K pathway activity was higher in T-ALL
patients who underwent relapse [61]. Owing to the
fundamental role of PI3K pathway in tumors and in
particular in T-ALL, we investigated the phosphorylation
status of AKT, a direct downstream target of PI3K, in
T-ALL cells. We have shown that in resistant T-ALL cell
lines and primary relapsed T-ALL blasts, nelarabine
alone caused an increase of AKT phosphorylation at
Ser473. Accordingly, PI3K inhibition with ZSTK-474
deeply sensitized T-ALL cells to nelarabine, while the
combination of nelarabine with either MEK or Bcl2
inhibitors was less synergistic in inducing cell death in
T-ALL cell lines. Because at present, it is impossible to
predict if patient could benefit from nelarabine
treatment, this study for the first time uncovered mecha-
nisms responsible for resistance to nelarabine in T-ALL
cells, paving the way to novel combination strategies,
able to overcome resistance and facilitate the bridge to
hematopoietic cell transplantation. Indeed, these findings
strongly suggest that combining nelarabine with inhibi-
tors of PI3K/AKT/mTOR signaling may represent a
possible strategy for the treatment of relapsed or refrac-
tory patients with T-ALL. In this sense, it should be
emphasized that a recent phase I/II clinical trial has
demonstrated that the mTOR inhibitor everolimus was
moderately effective in combination with hyper-CVAD
chemotherapy especially in relapsed/refractory T-ALL
patients [45].
Conclusions
Therefore, data obtained from this work could improve
the therapy of refractory/relapsed T-ALL through the
design of new regimens that could ameliorate clinical
care of patients and their outcome, providing more




Nelarabine, ZSTK-474, IPI-145, trametinib, CCI-779,
and ABT199 were kindly provided by Selleckchem
(Houston, TX, USA). Ara-G, insulin, transferrin, sodium
selenite (ITS), propidium iodide (PI), AMD3100, and
LY294002 were purchased from Sigma-Aldrich (St.
Louis, MO, USA). For western blotting analysis, all the
primary antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA) except for the anti-
bodies to CXCR4 and p-CXCR4 (Ser339) which were
from Abcam (Cambridge, UK) and antibodies to dGK
and dCK which were from Thermo Scientific (Thermo
Scientific, Waltham, MA, USA). AlexaFluor@-conjugated
antibodies were from Cell Signaling Technology or BD
Biosciences (Franklin Lakes, NJ, USA).
Cell cultures and patient samples
A panel of human T-ALL cell lines (HPB-ALL, DND41,
RPMI-8402, JURKAT, MOLT-4, MOLT-16, CEM-S,
CEM-R drug resistant, ALL-SIL, LOUCY, HSB-2, PEER,
KOPTK1, PF382, P12-ICHIKAWA) was employed. HS-5
human stromal cells were also employed to mimic bone
marrow microenvironment. All cell lines, except HS-5,
were from Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (DSMZ, Braunschweig,
Germany). HS-5 cells were from ATCC (Manassas, VA,
USA). Primary blast cells from relapsed T-ALL were ob-
tained, upon written informed consent in accordance
with the Declaration of Helsinki and the study has been
approved by the ethics committee (Independent Ethics
Committee of the University Hospital of Bologna “S.
Orsola-Malpighi”). Blasts from the bone marrow and
peripheral blood samples were obtained by density
gradient centrifugation over Lymphoprep (Nycomed UK,
Birmingham, UK). Cell cultures and primary T-ALL
refractory/relapsed lymphoblasts were grown in RPMI
1640 + ITS, supplemented with 10 or 20 % fetal bovine
serum (FBS), L-glutamine, and penicillin–streptomycin.
HS-5 human stromal cells were grown in MEM Alpha
Modification (Sigma-Aldrich) medium supplemented with
10 % FBS, L-glutamine, and penicillin–streptomycin.
Cell viability analysis
MTT (3-[4,5-dimethylthythiazol-2-yl]-2,5-diphenyltetra-
zolium bromide) assays were performed to assess the
sensitivity of cells to drugs, as previously reported [62].
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Annexin V-fluorescein isothiocyanate (FITC)/PI staining
To assess the extent of apoptosis induction, a flow cyto-
metric analysis of Annexin V-FITC/PI-stained samples
was performed. Analyses were performed on a FC500
flow cytometer (Beckman, Miami, FL, USA), with the
appropriate software (CXP, Beckman). At least 15,000
events per sample were acquired.
Quantification of p-H2AX (Ser139) (γH2AX) by flow
cytometry
Cells were treated with nelarabine (2 μM MOLT-4; 5 μM
Jurkat) and fixed in 70 % ethanol over night at −20 °C.
Afterwards, cells were rehydrated for 10 min at 4 °C in
PBS containing 4 % FBS and 0.1 % Triton X-100. Perme-
abilized cells were incubated with an Alexa Fluor 647
Mouse anti p-H2AX (Ser139) (BD Bioscience) at room
temperature. Fluorescence was measured by flow
cytometer on a FC500 flow cytometer (Beckman, Miami,
FL, USA), with the appropriate software (CXP, Beckman).
At least 10,000 events per sample were acquired.
Measurement of intracellular reactive oxygen species
(ROS) levels
ROS intracellular level was evaluated by using the fluor-
escent probe 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA). Cells (0.5 × 10
6/mL) were incubated with
nelarabine for 1 and 24 h; then, cells were washed twice
in HBSS and incubated with 5 μM H2DCFD for 20 min
at 37 °C. H2DCFDA is a small non-polar, non-
fluorescent molecule that diffuses into the cells, where it
is enzymatically deacetylated by intracellular esterases to
a polar non-fluorescent compound, which is oxidized to
the highly green fluorescent 2′,7′-dichlorofluorescein
(DCF). The fluorescence of oxidized probe was mea-
sured using a multiwell plate reader (Wallac Victor2,
PerkinElmer). Excitation wavelength was 485 nm, and
emission wavelength was 535 nm. Fluorescence values
were reported as the percentage of intracellular ROS in
respect to controls.
Western blot analysis
This was performed by standard methods, as previously
reported [62].
Bcl2, Bcl-xL, and ENT1/2 expression analyses by qRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Venlo, The Netherlands) according to the man-
ufacturer’s instructions, and 1 μg of total RNA was
reverse transcribed using High-Capacity cDNA Reverse
Transcription Kit (Thermo Scientific). Gene expression
was assessed using The TaqMan® Gene Expression Mas-
ter Mix and the assays Hs_01085704g1, Hs00155426m1,
Hs00608023_m1, and Hs00236329_m1, using the 7300
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). Results were normalized to the level of the ubi-
quitously expressed RNA 18S ribosomal 1 gene (RN18S,
Hs03928990_g1), and the Universal Human Reference
RNA (Agilent) was used as control. RNA 18S ribosomal 1
gene was used as a internal control gene (RN18S,
Hs03928990_g1). Results were expressed as 2−ΔCt (ΔCt
= [(CT gene of interest − CT internal control) to compare
the relative gene expression among samples, and as 2−ΔΔCt
(ΔΔCt = [(CT gene of interest − CT internal control)
sample − (CT gene of interest − CT internal control)
universal]) to compare gene expression of the treated cell
lines with that of untreated control [63].
Flow cytometric analysis of P-gp expression and P-gp dir-
ect dye efflux assay
These were performed essentially as described [64].
Co-culture with human HS-5 stromal cells
HS-5 stromal cells were grown in the lower chamber of
Transwell® six-well plates (Corning, New York, NY,
USA) containing a 0.4 μm of polyester membrane, then
T-ALL cells (375,000) were added to the upper chamber
and treated with nelarabine (2–5 μM). After 48 h, the
viability of treated cell lines grown either alone or
co-cultured was evaluated. Cells were collected and
analyzed for further experiments.
Combined drug effect analysis
The combination effect and a potential synergy were
evaluated from quantitative analysis of dose-effect
relationships as described previously [62]. For each
combination experiment, a combination index (CI)
number was calculated using the Biosoft CalcuSyn
software (Cambridge, UK).
Flow cytometric analysis of p-AKT (Ser473), p-ERK
(Thr202), and Bcl2 levels in T-ALL patient samples
Blasts from pediatric patients with T-ALL were fixed/
permeabilized in methanol 90 % for at least 30 min, then
washed in PBS with 4 % FBS. Cells were incubated with
primary antibodies conjugated to AlexaFluor® 488 or
647, from Cell Signaling. Isotype controls were employed
as well. Cells were analyzed on a FC500 flow cytometer
(Beckman Coulter) with the appropriate software (CXP,
Beckman Coulter). At least 15,000 events per sample
were acquired. Absolute cell count by flow cytometry
was performed using eBeads123 (Affimetrix eBios-
ciences, Santa Clara, CA, USA).
Statistical analysis
The data are presented as mean values from three separ-
ate experiments ± SD. Significant effects between
treatment and control groups in the in vitro studies were
analyzed using Student’s unpaired t test. Mann–Whitney
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test was used to statistically analyze the differences in
the two subgroups of sensitive/resistant to nelarabine
T-ALL cells.
Additional files
Additional file 1: Figure S1. DNA damage and ROS production. A.
Flow cytometric analysis of γH2AX in MOLT-4 and Jurkat sensitive to
nelarabine cells (upper panel). Percentages of γH2AX are shown in the
table (lower panel). B. Reactive oxygen species (ROS) production was
assessed in MOLT-4 and Jurkat sensitive T-ALL cell lines after 1 and 24 h
treatment with nelarabine. Fluorescence values (DCF) were reported as
the percentage of intracellular ROS in respect to controls. ROS increased
significantly in both 1- and 24-h treatment compared to controls in
MOLT-4 and Jurkat cells. Statistical analyses were performed with the
Dunnett’s multiple comparison test.
Additional file 2: Figure S2. Expression of dCK and dGK in T-ALL cell
lines. Western blotting analyses for the expression of dCK and dGK
proteins in T-ALL cell lines. Fifty micrograms of protein was blotted to
each lane. Antibody to β-actin served as a loading control. Molecular
weights are indicated on the right. One representative of two different
experiments is shown.
Additional file 3: Figure S3. Bcl2 expression in T-ALL cell lines. Western
blotting analyses for the basal expression of Bcl2 in untreated T-ALL cell
lines. Twenty micrograms of protein was blotted to each lane. Antibody
to β-actin served as a loading control. Molecular weights are indicated
on the right. Densitometric analysis was performed using a Chemidoc
810 Imager with the appropriate software (UVP, Upland, CA, USA), and for
each cell line, Bcl2 protein expression is indicated relatively to β-actin
expression.
Additional file 4: Figure S4. The combination of nelarabine and
ZSTK-474 is synergistic in CEM-R cells, which overexpress P-gp. Cell
viability assay of CEM-R cell line treated for 48 h with increasing
concentrations of nelarabine alone or combined with the pan PI3K p110
inhibitor ZSTK-474. One representative of two different experiments is
shown.
Additional file 5: Figure S5. Specific effects of nelarabine on PI3K/AKT
and MEK/ERK1/2 pathways. Western blotting analyses for the expression
of p-AKT and p-ERK in resistant T-ALL cell lines treated with the
specific inhibitors LY294002 (PI3K inhibitor), CCI-779 (mTOR allosteric
inhibitor) or trametinib (MEK1/2 inhibitor) alone or in combination with
nelarabine. Thirty micrograms of protein was blotted to each lane.
Antibody to β-actin served as a loading control. Molecular weights are
indicated on the right. CTRL: untreated cells; Nela and N: nelarabine at
10 μM; LY: LY294002 at 10 μM; CCI: CCI-779 at 100 nM; Tram: trametinib
at 1 μM. Cells were treated for 48 h.
Additional file 6: Figure S6. HS-5 stromal cells protect MOLT-4 cells
from nelarabine cytotoxicity at least in part through CXCL12/CXCR4
interactions. A. MTT assays of MOLT-4 cells growing alone or in co-culture
system with HS-5 cells and treated with nelarabine (2 μM for 48 h) in a
Transwell@ system. Three hundred seventy-five thousand MOLT-4 cells
were seeded in the upper chamber of the Transwell@ system. Results are
the mean of three different experiments ± SD. B. Western blot analysis for
p-ERK, p-CXCR4, and their total forms in MOLT-4 cells grown either in the
absence or the presence of HS-5 stromal cells in a Transwell@ system.
Nelarabine treatment (2 μM) was for 24 h. Fifty micrograms of protein
was blotted to each lane. Antibody to β-actin served as a loading control.
Molecular weights are indicated on the right. One representative of two
different experiments is shown.
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